A pilot randomized controlled trial of liraglutide 3.0 mg for binge eating disorder

被引:20
作者
Allison, Kelly C. [1 ]
Chao, Ariana M. [1 ,2 ]
Bruzas, Maija B. [1 ,4 ]
McCuen-Wurst, Courtney [1 ]
Jones, Elizabeth [1 ,5 ]
McAllister, Cooper [1 ,6 ]
Gruber, Kathryn [1 ,7 ]
Berkowitz, Robert, I [1 ,3 ]
Wadden, Thomas A. [1 ]
Tronieri, Jena S. [1 ]
机构
[1] Univ Penn, Perelman Sch Med, Dept Psychiat, 3535 Market St,Suite 3029, Philadelphia, PA 19104 USA
[2] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA
[3] Childrens Hosp Philadelphia, Dept Child & Adolescent Psychiat & Behav Sci, Philadelphia, PA 19104 USA
[4] Hlth Psychol Associates PC, Greeley, CO USA
[5] Cent Behav Hlth, Willow Grove, PA USA
[6] Univ Calif San Diego, La Jolla, CA 92093 USA
[7] Matrix Med Network, Scottsdale, AZ USA
来源
OBESITY SCIENCE & PRACTICE | 2023年 / 9卷 / 02期
关键词
binge eating disorder; binge episodes; eating disorder; liraglutide; loss of control eating; weight loss medication; OBESE-PATIENTS; WEIGHT-LOSS; DSM-IV; EFFICACY; QUESTIONNAIRE; INDIVIDUALS; TOPIRAMATE; VALIDATION; SEVERITY; ADULTS;
D O I
10.1002/osp4.619
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: To assess the efficacy of liraglutide 3.0 mg, a glucagon-like peptide-1 (GLP-1) receptor agonist, for binge eating disorder (BED). Methods: Adults with a body mass index (BMI) >= 27 kg/m(2) enrolled in a pilot, 17-week double-blind, randomized controlled trial of liraglutide 3.0 mg/day for BED. The primary outcome was number of objective binge episodes (OBEs)/week. Binge remission, weight change, and psychosocial variables were secondary outcomes. Mixed effect models were used for continuous variables, and generalized estimating equations were used for remission rates. Results: Participants (n = 27) were 44.2 +/- 10.6 years; BMI = 37.9 +/- 11.8 kg/m(2); 63% women; and 59% White and 41% Black. At baseline, the liraglutide group (n = 13) reported 4.7 +/- 0.7 OBEs/week, compared with 3.0 +/- 0.7 OBEs/week for the placebo group, p = 0.07. At week 17, OBEs/week decreased by 4.0 +/- 0.6 in liraglutide participants and by 2.5 +/- 0.5 in placebo participants (p = 0,37, mean difference = 1.2, 95% confidence interval 1.3, 2.0). BED remission rates of 44% and 36%, respectively, did not differ, Percent weight loss was significantly greater in the liraglutide versus the placebo group (5.2 +/- 1.0% vs. 0.9 +/- 0.7%, p = 0.005). Conclusion: Participants in both groups reported reductions in OBEs, with the liraglutide group showing clinically meaningful weight loss. A pharmacy medication dispensing error was a significant limitation of this study. Further research on liraglutide and other GLP-1 agonists for BED is warranted.
引用
收藏
页码:127 / 136
页数:10
相关论文
共 50 条
  • [1] Armodafinil in binge eating disorder: a randomized, placebo-controlled trial
    McElroy, Susan L.
    Guerdjikova, Anna I.
    Mori, Nicole
    Blom, Thomas J.
    Williams, Stephanie
    Casuto, Leah S.
    Keck, Paul E., Jr.
    INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY, 2015, 30 (04) : 209 - 215
  • [2] Naltrexone/bupropion for binge-eating disorder: A randomized, double-blind, placebo-controlled trial
    Grilo, Carlos M.
    Lydecker, Janet A.
    Jastreboff, Ania M.
    Pittman, Brian
    Mckee, Sherry A.
    OBESITY, 2023, 31 (11) : 2762 - 2773
  • [3] Lisdexamfetamine dimesylate in binge eating disorder: a placebo controlled trial
    Guerdjikova, Anna I.
    Mori, Nicole
    Blom, Thomas J.
    Keck, Paul E., Jr.
    Williams, Stephanie L.
    Welge, Jeffrey A.
    McElroy, Susan L.
    HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL, 2016, 31 (05) : 382 - 391
  • [4] Self-compassion training for binge eating disorder: A pilot randomized controlled trial
    Kelly, Allison C.
    Carter, Jacqueline C.
    PSYCHOLOGY AND PSYCHOTHERAPY-THEORY RESEARCH AND PRACTICE, 2015, 88 (03) : 285 - 303
  • [5] Naltrexone plus Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study
    Grilo, Carlos M.
    Lydecker, Janet A.
    Morgan, Peter T.
    Gueorguieva, Ralitza
    CLINICAL THERAPEUTICS, 2021, 43 (01) : 112 - 123
  • [6] EEG Neurofeedback in the Treatment of Adults with Binge-Eating Disorder: a Randomized Controlled Pilot Study
    Blume, Marie
    Schmidt, Ricarda
    Schmidt, Jennifer
    Martin, Alexandra
    Hilbert, Anja
    NEUROTHERAPEUTICS, 2022, 19 (01) : 352 - 365
  • [7] Naltrexone-Bupropion and Behavior Therapy, Alone and Combined, for Binge-Eating Disorder: Randomized Double-Blind Placebo-Controlled Trial
    Grilo, Carlos M.
    Lydecker, Janet A.
    Fineberg, Sarah K.
    Moreno, Jorge O.
    Ivezaj, Valentina
    Gueorguieva, Ralitza
    AMERICAN JOURNAL OF PSYCHIATRY, 2022, 179 (12) : 927 - 937
  • [8] Adding executive function training to cognitive behavioral therapy for binge eating disorder: A pilot randomized controlled trial
    Eichen, Dawn M.
    Strong, David R.
    Twamley, Elizabeth W.
    Boutelle, Kerri N.
    EATING BEHAVIORS, 2023, 51
  • [9] Cognitive Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge-Eating Disorder With Obesity: A Randomized Controlled Trial
    Grilo, Carlos M.
    Ivezaj, Valentina
    Tek, Cenk
    Yurkow, Sydney
    Wiedemann, Ashley A.
    Gueorguieva, Ralitza
    AMERICAN JOURNAL OF PSYCHIATRY, 2025, 182 (02) : 209 - 218
  • [10] Psychiatric comorbidity as predictor and moderator of binge-eating disorder treatment outcomes: an analysis of aggregated randomized controlled trials
    Lydecker, Janet A.
    Grilo, Carlos M.
    PSYCHOLOGICAL MEDICINE, 2022, 52 (16) : 4085 - 4093